ArticleNeurology and therapy2025

Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Italy.

Barbara Polistena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.